Log In Get Started
Press Releases March 26, 2026 08:00 PM

BOSS Zhipin Continued Share Repurchase, Total Repurchases Amount to Over RMB500 million in 2026

KANZHUN LIMITED continues aggressive share buyback, spending over RMB500 million in 2026 to boost shareholder value

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, trading as BOSS Zhipin on Nasdaq (BZ) and HKEX (2076), announced it repurchased 506,252 shares worth approximately RMB23.6 million on March 26, 2026. Year-to-date, the company has spent more than RMB500 million on share repurchases, signaling strong commitment to enhancing shareholder returns.

BOSS Zhipin Continued Share Repurchase, Total Repurchases Amount to Over RMB500 million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has executed share buybacks totaling over RMB500 million in 2026 so far.
  • The latest repurchase involved approximately 506,252 shares at a cost of RMB23.6 million on March 26.
  • This buyback program underscores the company's focus on returning value to shareholders and confidence in its financial position.

BEIJING, March 27, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB23.6 million to repurchase 506,252 ordinary shares on March 26. Year-to-date in 2026, the Company has deployed over RMB500 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.



Risks

  • The significant capital deployed to share repurchases may limit the company’s liquidity or investment in growth initiatives.
  • Market conditions or regulatory changes could affect the company’s ability to continue repurchasing shares at the same pace.
  • Potential fluctuations in share price may impact the effectiveness and timing of the buyback program.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026